Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma

Abstract

Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor–T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.

Keywords:

• bispecific antibodies
• BsAbs
• chimeric antigen receptor – T cell therapies
• CAR-T
• lenalidomide

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

GP has received honoraria from Curio Science and OncLive and has served on advisory board for Atara Biotherapeutics. BC received personal fees for consulting and/or member of advisory boards from Celgene, Morphosys, Kite, Epizyme, Beigene, Symbios, Lilly, and TG Therapeutics, personal fees from AbbVie, Gilead, Karyopharm, Merck, Glaxo Smith Kline, and Janssen/Pharmacyclics, during the conduct of the study. The authors report no other potential conflicts of interest for this work.